Patients dosed with an experimental Skye Bioscience obesity did not lose enough weight to meet the goals of a mid-stage study, dealing a setback to the biotech’s bid to revive a class of medicines once written off due to safety risks. Those complications did not emerge in the clinical trial, which Skye executives say suggest the drug may yet prove successful with higher dosing.

The Skye drug, nimacimab, is an antibody designed to block CB1, a receptor whose physiological roles include regulating appetite. San Diego-based Skye is evaluating the weekly injectable drug in a 136-patient Phase 2a study. The preliminary results reported Monday show participants who received Skye’s nimacimab as a monotherapy lost an average 1.52% of their body weight after 26 weeks compared to 0.26% weight los

See Full Page